Status and phase
Conditions
Treatments
About
The purpose of this study is to investigate the pharmacokinetics of donepezil HCl 3 mg in subjects with end-state renal disease who were receiving haemodialysis.
Full description
This is a randomised, single-center, open-label, single-dose, two-period crossover pharmacokinetics study of donepezil HCl tablets 3 mg in subjects receiving haemodialysis. Subjects will be or will not be receiving haemodialysis. After intervals of over 15 days, the subjects will be receiving the other treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects with end-stage renal disease who were receiving haemodialysis. Subject who are able and willing to give written informed consent.
Exclusion criteria
Subjects with known hypersensitivity to drugs or foods. Subjects with a corrected QT interval greater than 450 msec at Screening period.
Primary purpose
Allocation
Interventional model
Masking
6 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal